ArticleMicrobial biotechnology2020
Generation of a highly attenuated strain of Pseudomonas aeruginosa for commercial production of alginate.
Article in Microbial biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 69 citations in OpenAlex.
- Alginate Biosynthesis ofFood science & nutrition · 2026Article
- Attenuated Strains of Pseudomonas aeruginosa: A Promising Cell Factory for Rhamnolipid Production.Microbial biotechnology · 2025Review
- Cell walls: a comparative view of the composition of cell surfaces of plants, algae, and microorganisms.Journal of experimental botany · 2025Review
- Bacterial Species in Engineered Living Materials: Strategies and Future Directions.Microbial biotechnology · 2025Review
- Applying a polysaccharide lyase fromApplied and environmental microbiology · 2025Article
- Nano/Micro-Structural Supramolecular Biopolymers: Innovative Networks with the Boundless Potential in Sustainable Agriculture.Nano-micro letters · 2024Review
- Genome analysis of Pseudomonas strain 4B with broad antagonistic activity against toxigenic fungi.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Review
- Enhancing Soil Resilience: Bacterial Alginate Hydrogel vs. Algal Alginate in Mitigating Agricultural Challenges.Gels (Basel, Switzerland) · 2023Article
- Two-step conversion of polyethylene into recombinant proteins using a microbial platform.Microbial cell factories · 2023Article
- State of Innovation in Alginate-Based Materials.Marine drugs · 2023Review
- The two faces of pyocyanin - why and how to steer its production?World journal of microbiology & biotechnology · 2023Review
- Promising substitute of inconsistent algal alginates: exploring the biocompatible properties of di-O-acetylated, poly-L-guluronate-deficient alginate from soil bacteriumBiotechnologia · 2023Article
- Cold adaptedFrontiers in microbiology · 2023Review
- Pseudomonas aeruginosa isolate PM1 effectively controls virus infection and promotes growth in plants.Archives of microbiology · 2022Article
- Detection ofInternational journal of microbiology · 2022Article
- The Layered Encapsulation of Vitamin BFoods (Basel, Switzerland) · 2021Article
- Cloning, Expression and Characterization of UDP-Glucose Dehydrogenases.Life (Basel, Switzerland) · 2021Article
- Single-Cell Microgels for Diagnostics and Therapeutics.Advanced functional materials · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Alginate is an important polysaccharide that is commonly used as a gelling agent in foods, cosmetics and healthcare products. Currently, all alginate used commercially is extracted from brown seaweed. However, with environmental changes such as increasing ocean temperature and the increasing number of biotechnological uses of alginates with specific properties, there is an emerging need for more reliable and customizable sources of alginate. An alternative to seaweed for alginate production is Pseudomonas aeruginosa, a common Gram-negative bacterium that can form alginate-containing biofilms. However, P. aeruginosa is an opportunistic pathogen that can cause life-threatening infections in immunocompromised patients. Therefore, we sought to engineer a non-pathogenic P. aeruginosa strain that is safe for commercial production of alginate. Using a homologous recombination strategy, we sequentially deleted five key pathogenicity genes from the P. aeruginosa chromosome, resulting in the marker-free strain PGN5. Intraperitoneal injection of mice with PGN5 resulted in 0% mortality, while injection with wild-type P. aeruginosa resulted in 95% mortality, providing evidence that the systemic virulence of PGN5 is highly attenuated. Importantly, PGN5 produces large amounts of alginate in response to overexpression of MucE, an activator of alginate biosynthesis. The alginate produced by PGN5 is structurally identical to alginate produced by wild-type P. aeruginosa, indicating that the alginate biosynthetic pathway remains functional in this modified strain. The genetic versatility of P. aeruginosa will allow us to further engineer PGN5 to produce alginates with specific chemical compositions and physical properties to meet different industrial and biomedical needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.